olanzapine - Profile

What are the generic drug sources for olanzapine and what is the scope of patent protection?

Olanzapine is the generic ingredient in five branded drugs marketed by Am Regent, Anthea Pharma, Aspiro, Eugia Pharma, Omnivium Pharms, Qilu, Sandoz Inc, UBI, Cheplapharm, Ajanta Pharma Ltd, Apotex Inc, Aurobindo Pharma Ltd, Barr Labs Inc, Chartwell Molecular, Dr Reddys Labs Ltd, Hec Pharm, Hisun Pharm Hangzhou, Jubilant Generics, Macleods Pharms Ltd, Orbion Pharms, Pharmobedient, Strides Pharma Intl, Sun Pharm Inds, Torrent, Zydus Pharms, Alkem Labs Ltd, Cadila Pharms Ltd, Hikma, Indoco, Ivax Pharms Inc, Jiangsu Hansoh Pharm, Natco Pharma, Sunshine, Teva Pharms, Torrent Pharms Ltd, and Alkermes Inc, and is included in fifty-one NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There is one tentative approval for this compound.

Summary for olanzapine

US Patents:	14
Tradenames:	5
Applicants:	36
NDAs:	51

Generic filers with tentative approvals for OLANZAPINE

Applicant	Application No.	Strength	Dosage Form
		5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for olanzapine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	OLANZAPINE	olanzapine	POWDER;INTRAMUSCULAR	201741-001	Mar 20, 2012	AP	RX	No	No
Anthea Pharma	OLANZAPINE	olanzapine	POWDER;INTRAMUSCULAR	220323-001	Mar 5, 2026	AP	RX	No	No
Aspiro	OLANZAPINE	olanzapine	POWDER;INTRAMUSCULAR	217466-001	Mar 22, 2023	AP	RX	No	No
Eugia Pharma	OLANZAPINE	olanzapine	POWDER;INTRAMUSCULAR	210968-001	Oct 22, 2020	AP	RX	No	No
Omnivium Pharms	OLANZAPINE	olanzapine	POWDER;INTRAMUSCULAR	219048-001	Jan 23, 2026	AP	RX	No	No
Qilu	OLANZAPINE	olanzapine	POWDER;INTRAMUSCULAR	218116-001	May 16, 2025	AP	RX	No	No

Expired US Patents for olanzapine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000	5,736,541
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-001	Apr 6, 2000	5,817,655
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-004	Apr 6, 2000	5,605,897
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-002	Sep 30, 1996	6,960,577
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-004	Apr 6, 2000	5,457,895
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000	5,817,656

EU/EMA Drug Approvals for olanzapine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Zyprexa Velotab	olanzapine	EMEA/H/C/000287AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	no	no	no	2000-02-03
Eli Lilly Nederland B.V.	Zypadhera	olanzapine	EMEA/H/C/000890Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.	Authorised	no	no	no	2008-11-19
Eli Lilly Nederland B.V.	Zyprexa	olanzapine	EMEA/H/C/000115Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.	Authorised	no	no	no	1996-09-27
Krka	Zalasta	olanzapine	EMEA/H/C/000792Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-09-27
Mylan Pharmaceuticals Limited	Olanzapine Mylan	olanzapine	EMEA/H/C/000961AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2008-10-06
Teva B.V.	Olanzapine Teva	olanzapine	EMEA/H/C/000810AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-12-12

Investment Scenario, Market Dynamics, and Financial Trajectory for Olanzapine

Last updated: February 3, 2026

---

Executive Summary

Olanzapine, an atypical antipsychotic, remains a prominent drug within the psychiatric treatment landscape. Originally approved by the FDA in 1996, it addresses schizophrenia, bipolar disorder, and treatment-resistant depression. Globally, the olanzapine market exhibits consistent growth driven by rising mental health awareness, expanding approved indications, and unmet clinical needs. With an estimated 2023 global market value exceeding USD 4 billion, the investment outlook involves assessing revenue streams, competitive positioning, pipeline developments, and regulatory landscape. This report details the current market structure, growth drivers, challenges, and future projections, providing a comprehensive framework for stakeholders considering olanzapine-related investments.

---

1. Market Overview

Aspect	Details
Global Market Size (2023)	USD 4.5 billion (approximate)
CAGR (2023-2028)	3.2%
Key Regions	North America (40%), Europe (25%), Asia-Pacific (20%), ROW (15%)
Major Players	Eli Lilly, Teva Pharmaceuticals, Mylan/Nuvax, Sun Pharma, Others

Source: IQVIA, Market Research Future (2023 estimates)

---

2. Market Drivers

Driver Factors	Impact Details
Increasing prevalence of schizophrenia and bipolar disorders	WHO estimates 1 in 300 people worldwide affected by schizophrenia; bipolar disorder affects approximately 1-2% of global population, thus expanding therapeutic demand.
Growing acceptance of atypical antipsychotics	Shift from first-generation antipsychotics to safer, better-tolerated medications like olanzapine enhances market size.
Expanded indications	Additional approvals for treatment-resistant depression and off-label uses in agitation and aggression improve revenue streams.
Rising mental health awareness	Governments and healthcare providers prioritize mental health policies, boosting prescriptions.
Patent life considerations	Patent expiration scheduled around 2024-2028 in key markets, opening generic competition.

---

3. Market Challenges and Risks

Challenge / Risk	Impact Details
Generic drug entry post-patent expiry	Erosion of brand market share, leading to revenue decline.
Side effect profiles	Metabolic syndrome and weight gain can limit patient adherence.
Regulatory scrutiny	Increased oversight on safety and off-label use.
Competition with newer agents	Third-generation antipsychotics (e.g., aripiprazole, brexpiprazole) offer alternative treatments.

---

4. Financial Trajectory and Revenue Forecast

Fiscal Year	Estimated Global Sales (USD billions)	Key Factors
2023	4.5	Mature product, controlled market share
2024-2025	4.2 - 4.3	Patent expiry in major markets, increasing generic penetration
2026-2028	3.0 - 3.5	Continued generic competition, potential pipeline contributions
2029+	Stabilization at lower levels	Market stabilization and emergence of new therapies

Note: Writings from IQVIA and EvaluatePharma suggest a decline of approximately 15-25% post-patent expiration, with some regions experiencing faster erosion.

---

5. Pipeline and Innovation Potential

Area of Development	Status & Outlook
New formulations	Long-acting injectables (LAIs) for sustained release gaining popularity. Examples include olanzapine pamoate (Zyprexa Relprevv).
Combination therapies	Combining olanzapine with mood stabilizers or antidepressants to expand indications.
Pharmacogenomics-driven personalization	Research ongoing for genotype-guided dosing to improve safety and efficacy.
Development of safer analogs	Candidates aiming to moderate metabolic side effects are under preclinical/clinical studies.

---

6. Competitive Landscape

Company	Market Share	Core Products	Differentiators
Eli Lilly (Zyprexa)	~35%	Zyprexa (olanzapine)	Pioneered olanzapine's clinical market
Teva Pharmaceuticals	~20%	Generic olanzapine	Cost leadership, global distribution
Mylan/Nuvax	~10%	Generic olanzapine	Broad market reach
Sun Pharma	~8%	Generic formulations	Competitive pricing
Others	27%	Various biosimilars/patents	Competitive dynamics

Note: Dominance in branded sales, with generics rapidly capturing post-patent markets.

---

7. Policy and Regulatory Environment

Region	Key Policies	Impact on Market
United States	FDA approval for generics, ANDAs process	Patent cliff imminent; increased generic approvals
European Union	EMA guidelines for off-label use, DEPAR approvals	Regulatory scrutiny influencing prescribing practices
Asia-Pacific	Variations in patent protections; imports and local manufacturing	Growing markets with evolving patent laws

---

8. Investment Opportunities

Opportunity Type	Description	Risks / Considerations
Strategic Licensing	Partnering with biotech for pipeline advancements	Dependence on regulatory approval success
Business Development	Acquiring generic assets pre- or post-patent expiry	Market saturation, pricing pressures
R&D Innovations	Funding studies on new formulations or safer analogs	High R&D expenditures, uncertain outcomes
Market Expansion	Focused entry into emerging markets with increasing healthcare access	Regulatory barriers, pricing constraints

---

9. Comparative Analysis of Olanzapine and Alternative Drugs

Parameter	Olanzapine	Aripiprazole	Risperidone
Approval Year	1996	2002	1994
Market Share (2023)	Largest among atypical antipsychotics	Growing, especially in bipolar disorder	Significant, but declining post-generics
Side Effect Profile	Weight gain, metabolic issues	Lower metabolic risk, akathisia	Prolactin elevation, extrapyramidal symptoms
Dosage Range	5-20 mg/day	2-30 mg/day	1-6 mg/day
Route of Administration	Oral, injection (LAI)	Oral, LAI	Oral, LAI

---

10. Future Market Trajectory: Key Insights

• Post-patent expiration, olanzapine's revenues will decline, yet branded formulations like Zyprexa Relprevv and new delivery systems (injectables) can sustain niche markets.
• Market growth will be sustained by expanding indications, especially in Asia-Pacific, where mental health awareness and access are rising.
• The pipeline of digital health integrations and pharmacogenomics signifies trajectory toward personalized medicine.
• Competition from other atypicals and emerging therapeutics may expand the treatment landscape but should not immediately displace olanzapine's core position.

---

Key Takeaways

• Market valuation for olanzapine is projected to decline from USD 4.5 billion in 2023 to approximately USD 3.0-3.5 billion by 2028 due to patent expiries and generic competition.
• Growth drivers include increasing global prevalence of psychiatric conditions, off-label applications, and innovations in drug delivery.
• Risks involve regulatory scrutiny, side effect concerns, and competitive advancements with newer pharmacotherapies.
• Investment focus should pivot from branded olanzapine to generics, biosimilars, and pipeline innovations targeting safety and personalized treatment.
• Market expansion opportunities are prominent in emerging markets with expanding healthcare infrastructure and increasing mental health awareness.

---

FAQs

Q1: When will olanzapine patents expire in major markets, and how will this impact revenue?
The primary patents in the U.S. expired around 2015-2016, with some secondary patents ending between 2024-2028. Patent expiration typically leads to rapid generic entry, causing substantial revenue declines—estimated at 15-25% in subsequent years.

Q2: What are key regulatory considerations affecting olanzapine's market?
Regulatory agencies emphasize safety profiles, particularly metabolic side effects. Approval of generic formulations depends on bioequivalence, while evolving guidelines may restrict off-label uses.

Q3: How does olanzapine compare to newer atypical antipsychotics?
Olanzapine remains a market leader due to historical efficacy. However, newer agents offer improved side effect profiles, which influence prescribing patterns, especially in long-term management.

Q4: What opportunities exist for pipeline development around olanzapine?
Developments include long-acting injectable formulations, safer analogs with fewer metabolic effects, and digital adherence tools that can improve patient outcomes.

Q5: How do regional differences influence olanzapine investment?
Emerging markets like India, China, and Southeast Asia present growth opportunities driven by increasing mental health awareness and healthcare access, though regulatory regimes differ.

---

Sources

1. IQVIA Pharma Services (2023). Global Pharma Market Reports.
2. Market Research Future (2023). Pharmaceuticals Market Trends & Forecasts.
3. WHO (2022). Mental Health Atlas.
4. FDA (2022). Olanzapine Label and Patent Data.
5. EvaluatePharma (2023). Pharmaceutical Revenue Forecasts.